Physician profile
Ryan C Singerman
NPI 1588950901
$1,782.40
in general payments reported to CMS, 2019-2025
18 companies · $34.47 in 2025
The $34.47 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,451 · 2020: $186 · 2023: $49.47 · 2024: $61.50 · 2025: $34.47.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $145.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $145.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $338.44 | 2019-2023 | Wegovy |
| Glaxosmithkline, LLC. | $221.32 | 2019-2025 | Shingrix, Arexvy, Bexsero |
| Pfizer INC. | $217.88 | 2019-2024 | |
| Astrazeneca Pharmaceuticals Lp | $217.17 | 2019-2020 | |
| Lilly USA, LLC | $167.99 | 2019-2024 | Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $140.78 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $114.97 | 2019 | |
| Sanofi-Aventis U.S. LLC | $101.51 | 2019 | |
| Astellas Pharma US INC | $50.57 | 2019-2020 | |
| Supernus Pharmaceuticals, INC. | $46.76 | 2019-2020 | |
| Abbvie INC. | $36.70 | 2019-2025 | |
| Amarin Pharma, INC. | $29.02 | 2019 | |
| Amgen INC. | $26.31 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $18.57 | 2019 | |
| Becton, Dickinson and Company | $14.90 | 2024 | Bd Max System, Bd Max Instrument |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arbor Pharmaceuticals, INC. | $14.13 | 2019 | |
| Janssen Pharmaceuticals, INC | $13.48 | 2019 | |
| Eisai INC. | $11.90 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Singerman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.